Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO ...

Genentech, part of the Roche Group (OTCQX:RHHBY), said that a late-stage study testing Lunsumio, along with Polivy, showed ...

In this interview with TRUST-I and TRUST-II trial investigator, Jorge J. Nieva, MD, USC Keck School of Medicine, he walks through the design of the trials, the results that supported the FDA approval, ...

Explore our Hot Topics in UHPLC companion and the Advances in HPLC supplement, curated by conference organizer Gert Desmet, for in-depth insights and expert perspectives. During HPLC 2025, a major ...

In this video, Ian W. Flinn, MD, PhD, discusses the phase 2 MorningSun study evaluating fixed-duration subcutaneous mosunetuzumab in patients with previously untreated, high-tumor burden follicular ...

This well-tolerated investigational combination therapy avoids traditional chemotherapy and may be suitable for outpatient community care These data demonstrate Roche's commitment to providing options ...

After five years of unprecedented momentum, the ADC field now finds itself at an interesting inflection point. With more ...

Dapirolizumab pegol, a novel CD40L inhibitor, is superior to placebo for achieving low disease activity and remission in ...

Genomic assays play a critical role in guiding treatment decisions for patients with early-stage invasive breast cancer by providing prognostic and predictive insights. In a live Community Case Forum ...